Key Transaction Details

Cipla Limited has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("CTTQ"), a subsidiary of Sino Biopharmaceutical Limited ("SBP Group"), for Rolditamig Deuderuxtecan, also known as TQB2102.

Under the agreement, Cipla receives exclusive rights to develop and commercialize TQB2102 in India, South Africa, and 5 other emerging markets. Cipla will be responsible for local clinical development, regulatory activities, and commercialization in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.

Product Information

Rolditamig Deuderuxtecan (TQB2102) is a next-generation HER2 dual-epitope bispecific antibody-drug conjugate (ADC) independently developed by SBP Group. The drug simultaneously binds to the ECD II and ECD IV domains of HER2 and incorporates a cleavable linker and topoisomerase I inhibitor payload.

The drug has received three Breakthrough Therapy Designations from the Center for Drug Evaluation of China's National Medical Products Administration. It is currently being evaluated for HER2-low and HER2-positive breast cancer, colorectal cancer, and biliary tract cancer across multiple treatment settings.

Strategic Rationale

The collaboration aims to accelerate local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals. The partnership combines SBP Group's differentiated late-stage oncology asset and development/manufacturing capabilities with Cipla's established regulatory, medical, market access, and commercial presence across the licensed territories.

Management Commentary

Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla, stated: "At Cipla, innovation is central to our mission of expanding access to therapies that address unmet patient needs. Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate."

Eric Tse, CEO of SBP Group, commented: "Expanding global access to medicines developed by SBP Group is a central part of our strategy. TQB2102 has demonstrated encouraging clinical potential across different HER2-expressing breast cancer populations."

Financial Impact

Financial impact not quantified in the disclosure.

Effective Date

Agreement signed on 31st August, 2026.